Concurrent use of methotrexate and celecoxib increases risk of silent liver fibrosis in rheumatoid arthritis patients with subclinical reduced kidney function

Clinical Rheumatology

Volumn 33, Issue 10, 2014, Pages 1415-1423

  Park, Jin Su ^a   Park, Min Chan ^a   Park, Yong Beom ^a   Lee, Soo Kon ^a   Lee, Sang Won ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Celecoxib; Estimated glomerular filtration rate; Liver fibrosis; Methotrexate; Rheumatoid arthritis; Transient elastography

Indexed keywords

CELECOXIB; CHOLESTEROL; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; URIC ACID; ANTIRHEUMATIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; BODY MASS; DRUG EFFECT; ECHOGRAPHY; ELASTOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; KIDNEY INJURY; LIVER FIBROSIS; LIVER FUNCTION; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RIGIDITY; RISK FACTOR; SILENT LIVER FIBROSIS; TRANSIENT ELASTOGRAPHY; TREATMENT DURATION; URINALYSIS; AGED; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; CROSS-SECTIONAL STUDY; DRUG COMBINATION; INCIDENCE; KIDNEY; LIVER CIRRHOSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; PILOT STUDY; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CROSS-SECTIONAL STUDIES; CYCLOOXYGENASE 2 INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; KIDNEY; LIVER CIRRHOSIS; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PILOT PROJECTS; PYRAZOLES; RISK FACTORS; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84937512064     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2719-7     Document Type: Article

References (21)

1. Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344(12):907–16
2. Finckh A, Liang MH, van Herckenrode CM, de Pablo P (2006) Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 55(6):864–72
3. Weinblatt ME, Weissman BN, Holdsworth DE, Fraser PA, Maier AL, Falchuk KR et al (1992) Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum 35(2):129–37
4. Salliot C, van der Heijde D (2009) Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68(7):1100–4
5. Barbero-Villares A, Mendoza Jiménez-Ridruejo J, Taxonera C, López-Sanromán A, Pajares R, Bermejo F et al (2012) Evaluation of liver fibrosis by transient elastography (Fibroscan®) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. Scand J Gastroenterol 47(5):575–9
6. Kremer JM, Alarcón GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ et al (1994) Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity American College of Rheumatology. Arthritis Rheum 37(3):316–28
7. Weinblatt ME, Kaplan H, Germain BF, Merriman RC, Solomon SD, Wall B et al (1991) Methotrexate in rheumatoid arthritis: effects on disease activity in a multicenter prospective study. J Rheumatol 18(3):334–8
8. Nozaki Y, Kusuhara H, Kondo T, Iwaki M, Shiroyanagi Y, Nakayama H et al (2007) Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J Pharmacol Exp Ther 322(3):1162–70
9. Maeda A, Tsuruoka S, Kanai Y, Endou H, Saito K, Miyamoto E et al (2008) Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells. Eur J Pharmacol 596(1–3):166–72
10. Maeda A, Tsuruoka S, Ushijima K, Kanai Y, Endou H, Saito K et al (2010) Drug interaction between celecoxib and methotrexate in organic anion transporter 3-transfected renal cells and in rats in vivo. Eur J Pharmacol 640(1–3):168–71
11. Karim A, Tolbert DS, Hunt TL, Hubbard RC, Harper KM, Geis GS (1999) Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 26(12):2539–43
12. Colebatch AN, Marks JL, van der Heijde DM, Edwards CJ (2012) Safety of nonsteroidal antiinflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl 90:62–73
13. Hübner G, Sander O, Degner FL, Türck D, Rau R (1997) Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis. J Rheumatol 24(5):845–51
14. Schwartz JI, Agrawal NG, Wong PH, Miller J, Bachmann K, Marbury T et al (2009) Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Clin Pharmacol 49(10):1202–9
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–24
16. Lee SW, Park HJ, Kim BK, Han KH, Lee SK, Kim SU et al (2012) Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. Arthritis Res Ther 14(5):R232
17. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group (2005) The metabolic syndrome—a new worldwide definition. Lancet 366(9491):1059–62
18. Lujan PR, Chiurchiu C, Douthat W, de Arteaga J, de la Fuente J, Capra RH et al (2012) CKD-EPI instead of MDRD for candidates to kidney donation. Transplantation 94(6):637–41
19. Kim SU, Choi GH, Han WK, Kim BK, Park JY, Kim do Y et al (2010) What are ‘true normal’ liver stiffness values using FibroScan?: a prospective study in healthy living liver and kidney donors in South Korea. Liver Int 30(2):268–74
20. Matsushita K, Tonelli M, Lloyd A, Levey AS, Coresh J, Hemmelgarn BR, Alberta Kidney Disease Network (2012) Clinical risk implications of the CKD Epidemiology Collaboration (CKD-EPI) equation compared with the Modification of Diet in Renal Disease (MDRD) Study equation for estimated GFR. Am J Kidney Dis 60(2):241–9
21. Murakami Y, Yamazaki K, Sakauchi N, Ogasawara H, Yamashita N, Masuda T et al (1998) A one-month repeated oral dose toxicity study of methotrexate in unilaterally nephrectomized rats. J Toxicol Sci Suppl 5:681–99